Abstract
Targeting the Adenosine—Adenosine Deaminase-1 Axis to Restore HIV-Specific CD8+ T Cell Function 2309228
The Journal of immunology (1950), v 215(Supplement_1), vkag1411511
01 Aug 2026
Featured in Collection : Drexel's Newest Publications
Abstract
Abstract
Introduction
Despite suppressive antiretroviral therapy (ART), HIV reservoirs rapidly rebound upon treatment interruption, driven in part by progressive dysfunction of HIV-specific CD8+ T cells. Current strategies targting CD8+T cell dysfunction in cancer show limited benefit in people living with HIV (PLWH), underscoring the need for alternative approaches tailored to the unique immunological landscape of HIV infection. Adenosine (ADO) signaling is a potent immunoregulatory pathway regulated by adenosine deaminase-1 (ADA-1) that becomes dysregulated in PLWH and is associated with viral persistence. However, more work is needed to define its direct contribution to HIV-specific CD8+ T-cell dysfunction.
Methods
Using primary samples from PLWH, we applied three complementary approaches: (1) multi-omic and phenotypic profiling of tetramer-sorted HIV- and CMV-specific CD8+ T cells to assess regulation of ADA and ADO-signaling components; (2) ex vivo functional assays measuring cytokine production and degranulation following ADO or 2-chloroadenosine exposure with ADA-1 inhibition; and (3) CD8-targeted lipid nanoparticles (CD8-ADA-LNPs) to selectively deliver ADA-1 mRNA and assess functional improvement.
Results
HIV-specific CD8+ T cells exhibited repression of the ADA locus, increased expression of CD39 and the A2a adenosine receptor, indicating potential heightened sensitivity to ADO-mediated suppression. Functionally, ADO-exposure impaired CD8+ T-cell function, dependent on ADA-1. Targeted ADA-1 mRNA delivery via CD8-ADA-LNPs restored ADA-1 expression and improved antigen-specific CD8+ T-cell function in PLWH ex vivo.
Conclusion
These findings identify dysregulated ADO signaling and ADA-1 deficiency as contributors to HIV-specific CD8+ T-cell dysfunction and establish targeted ADA-1 delivery as a novel strategy to enhance CD8+ T-cell function. This approach provides a framework for targeting ADO-mediated immune suppression of CD8+T cells in HIV and other disease landscapes, including cancer.
Funding Source
Part of this work was funded by NIH grant to Dr. Elias K Haddad (# U19AI128910-04S1)
Topic Categories
Translational and Interventional Immunology (TI)
Metrics
1 Record Views
Details
- Title
- Targeting the Adenosine—Adenosine Deaminase-1 Axis to Restore HIV-Specific CD8+ T Cell Function 2309228
- Creators
- Arden Edgerton - Drexel UniversityDillon O’NeillDavid Joyner - Drexel UniversityEmily Konopka - Drexel UniversityTianyu Lu - Children's Hospital of PhiladelphiaTian Mi - St. Jude Children's Research HospitalBenjamin Youngblood - St. Jude Children's Research HospitalLaura Vella - Children's Hospital of PhiladelphiaMohamad Gabriel Alameh - University of PennsylvaniaMichele Kutzler - Drexel UniversityElias Haddad - Drexel University
- Publication Details
- The Journal of immunology (1950), v 215(Supplement_1), vkag1411511
- Publisher
- Oxford University Press; OXFORD
- Number of pages
- 1
- Grant note
- NIH: U19AI128910-04S1
Part of this work was funded by NIH grant to Dr. Elias K Haddad (# U19AI128910-04S1)
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Microbiology and Immunology; Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:001834121000001
- Other Identifier
- 991022200655304721